Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's LTM Mar 2026 revenue of $0 is the 5th highest of the 8 companies compared; the peer median is $31K.
PLYX Competitors Peer median
Revenue for PLYX and competitors
Company Period LTM YoY 3-year CAGR
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$28.22M +20.1%+17.1%
PTHSPelthos Therapeutics Inc.LTM Mar 2026$27.7M ——
CBIOCrescent Biopharma, Inc.LTM Mar 2026$11.88M —+424.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$31K -52.3%-92.5%
PLYXPolaryx Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
JBIOJade Biosciences, Inc.LTM Mar 2026$0 ——
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ——
KLRSKalaris Therapeutics IncLTM Mar 2026$0 ——
Peer median (excluding PLYX) $31K-16.1%+17.1%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development2.77M2.81M6.27M
Selling, General & Admin1.01M1.54M1.56M
Operating Expenses3.78M4.35M7.82M
Depreciation & Amortization000
EBITDA(3.78M)(30.36M)(8.99M)
EBITDA Margin———
Operating Income(3.78M)(4.35M)(7.82M)
Operating Margin———
Interest Income000
Interest Expense000
Other Income / Expenses2K(26M)(1.16M)
Income Before Tax(3.78M)(30.36M)(8.99M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(3.78M)(30.36M)(8.99M)
Net Margin———
EPS (Basic)(0.02)(0.16)(0.19)
EPS (Diluted)(0.02)(0.16)(0.19)
Weighted Avg Shares189.37M189.37M47.34M
Weighted Avg Shares (Diluted)189.37M189.37M47.34M

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.